STAT+: 曾冲刺千亿市值的Alnylam,急需解决心脏药物难题
STAT+: Alnylam, once in the hunt to be a $100 billion biotech, needs to solve its heart drug problem
Alnylam销售增长放缓,股价大跌。该公司凭借 blockbuster 心肌病治疗药Amvuttra,市值一度逼近Vertex的1000亿美元大关;但如今增长遇阻,心脏管线亟待突破。作者Adam Feuerstein回顾了其在2025年8月撰写的"Alnylam将成下一个Vertex"的观点,坦言当前形势已发生变化。
With sales growth slowing, the company’s stock price has tumbled
![]()
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.
Accountability check: Let’s talk about my “Alnylam is the next Vertex” take from the Aug. 7, 2025, edition of this newsletter.
Alnylam and Vertex are not direct competitors, but I was intrigued by the possibility that Alnylam’s rapidly accelerating growth — fueled by sales of its blockbuster cardiomyopathy treatment Amvuttra — could push its $60 billion market value equal to or higher than Vertex’s $100 billion market cap in the near future.
STAT+ Exclusive Story
Already have an account? Log in

This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
-
Senior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
来源:STAT 主站 · statnews.com